Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4464889
Max Phase: Preclinical
Molecular Formula: C43H49N11O7
Molecular Weight: 831.93
Molecule Type: Unknown
Associated Items:
ID: ALA4464889
Max Phase: Preclinical
Molecular Formula: C43H49N11O7
Molecular Weight: 831.93
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(CC(=O)NCCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cn3)nc2n(C2CCCC2)c1=O
Standard InChI: InChI=1S/C43H49N11O7/c1-25-30-23-47-43(50-38(30)53(27-8-3-4-9-27)41(60)36(25)26(2)55)48-33-14-12-28(22-46-33)52-20-18-51(19-21-52)24-35(57)45-17-6-5-16-44-31-11-7-10-29-37(31)42(61)54(40(29)59)32-13-15-34(56)49-39(32)58/h7,10-12,14,22-23,27,32,44H,3-6,8-9,13,15-21,24H2,1-2H3,(H,45,57)(H,49,56,58)(H,46,47,48,50)
Standard InChI Key: ZDYIWDFMTLECCN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 831.93 | Molecular Weight (Monoisotopic): 831.3816 | AlogP: 3.09 | #Rotatable Bonds: 14 |
Polar Surface Area: 220.93 | Molecular Species: NEUTRAL | HBA: 15 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.15 | CX Basic pKa: 6.22 | CX LogP: 2.59 | CX LogD: 2.57 |
Aromatic Rings: 4 | Heavy Atoms: 61 | QED Weighted: 0.08 | Np Likeness Score: -1.10 |
1. Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, Natarajan A.. (2019) Selective degradation of CDK6 by a palbociclib based PROTAC., 29 (11): [PMID:30935795] [10.1016/j.bmcl.2019.03.035] |
Source(1):